A Prospective, Comparative, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy (CARIN)

Trial Profile

A Prospective, Comparative, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy (CARIN)

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2016

At a glance

  • Drugs CMX 2043 (Primary)
  • Indications Acute kidney injury; Heart disorders
  • Focus Therapeutic Use
  • Acronyms CARIN
  • Sponsors Ischemix
  • Most Recent Events

    • 03 May 2016 Primary endpoint, (Prevention of acute kidney injury (AKI) ) has not been met, according to an Ischemix media release.
    • 03 May 2016 According to an Ischemix media release, company is reviewing post hoc analyses of certain patient subgroups for evidence of potential benefit of the drug.
    • 22 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top